Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial

• Clinical Activity of IMU-838 Confirmed Based on Multiple Secondary Endpoints, Including Clinically Meaningful Improvements in Time to Clinical Recovery and Clinical Improvement –
• Primary and Key Secondary Endpoints Were Not Evaluable Due to the Very Low Rates of Serious Complications in the Population of Hospitalized Patients With Moderate COVID-19 –
• High-Risk Patients and Patients Aged Over 65 Years Experienced a More Substantial Treatment  Effect of IMU-838 –
• Robust Anti-Inflammatory Effect Observed, Based on a More Effective Reduction of C-Reactive  Protein (CRP) in IMU-838 Treated Patients, as Compared to Placebo –
• Initial Data From a Post Hoc Analysis of “Long COVID” Symptoms Indicates That IMU-838 May Have the Potential to Contribute to the Prevention of Long-Term Fatigue –

Please see the link below to the full article

Immunic, Inc. Announces That Oral Treatment IMU-838 Shows Evidence of Clinical Activity in Moderate COVID-19 in Phase 2 CALVID-1 Trial